Reirradiation in head and neck recurrent or second primary tumor: Efficacy, safety, and prognostic factors

Tumori

Volumn 101, Issue 5, 2015, Pages 585-592

  Buglione, Michela ^a   Maddalo, Marta ^a   Mazzeo, Ercole ^b   Bonomo, Pierluigi ^c   Spiazzi, Luigi ^d   Bruni, Alessio ^b   Paiar, Fabiola ^c   Triggiani, Luca ^a   Greto, Daniela ^c   Rubino, Laura ^b   Livi, Lorenzo ^c   Bertioni, Filippo ^b   Magrini, Stefano Maria ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d SPEDALI CIVILI   (Italy)

Author keywords

Head and neck cancer; Prognostic factors; Reirradiation

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CAROTID ARTERY HEMORRHAGE; CAROTID ARTERY INJURY; CAROTID ARTERY STENT; CHARLSON COMORBIDITY INDEX; CHEMORADIOTHERAPY; COMORBIDITY; CONFORMAL RADIOTHERAPY; DERMATITIS; DYSPHAGIA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; JAW OSTEONECROSIS; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MYELITIS; OVERALL SURVIVAL; PATIENT SAFETY; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE; RE-IRRADIATION; SECOND CANCER; SOFT TISSUE NECROSIS; STEREOTACTIC BODY RADIATION THERAPY; THROMBOEMBOLISM; TISSUE NECROSIS; TRISMUS; XEROSTOMIA; ADULT; ADVERSE EFFECTS; DISEASE FREE SURVIVAL; HEAD AND NECK NEOPLASMS; KAPLAN MEIER METHOD; MEDICAL RECORD; MIDDLE AGED; MORTALITY; NEOPLASMS, SECOND PRIMARY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PATIENT SAFETY; PROGNOSIS; RADIOTHERAPY DOSAGE; RE-IRRADIATION; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84955688134     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000368     Document Type: Article

References (35)

1. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamouscell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949-955.
2. Eskander A, Merdad M, Irish JC, et al. Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck. 2014;36(12):1820-1834.
3. Garden AS, Kies MS, Morrison WH, et al. Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century. Radiat Oncol. 2013;8(1):21.
4. Bernier J, Domenge C, Ozsahin M, et al; European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350(19):1945-1952.
5. Jones AS, Bin Hanafi Z, Nadapalan V, Roland NJ, Kinsella A, Helliwell TR Do positive resection margins after ablative surgery for head and neck cancer adversely affect prognosis? A study of 352 patients with recurrent carcinoma following radiotherapy treated by salvage surgery. Br J Cancer. 1996;74(1):128-132.
6. Ridge JA. Squamous cancer of the head and neck: surgical treatment of local and regional recurrence. Semin Oncol. 1993; 20(5):419-429.
7. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000; 110(3 Pt 2)(Suppl 93):1-18.
8. Wong LY, Wei WI, Lam LK, Yuen AP Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25(11):953-959.
9. Agra IM, Carvalho AL, Ulbrich FS, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck. 2006;28(2):107-113.
10. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245-1251.
11. Gibson MK, Li Y, Murphy B, et al; Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15): 3562-3567.
12. Lartigau EF, Tresch E, Thariat J, et al. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiother Oncol. 2013; 109(2):281-285.
13. Balermpas P, Keller C, Hambek M, et al. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys. 2012;83(3):e377-e383.
14. Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;80(3):669-676.
15. Comet B, Kramar A, Faivre-Pierret M, et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012;84(1):203-209.
16. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of lowdose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25(30): 4800-4805.
17. Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol. 2006; 78(3): 306-312.
18. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281-288.
19. Duprez F, Madani I, Bonte K, et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol. 2009;93(3):563-569.
20. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006;64(2):382-391.
21. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol. 1998;16(11):3556-3562.
22. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. 2009 May. Available at: http://evs.nci.nih.gov/. Accessed June 10, 2015.
23. Karnofsky Performance Status Scale definitions rating (%) criteria. Available at: http://www.npcrc.org/files/news/karnofsky-performance-scale.pdf. Accessed June 6, 2015.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
25. Singh B, Bhaya M, Stern J, et al. Validation of the Charlson Comorbidity Index in patients with head and neck cancer: a multiinstitutional study. Laryngoscope. 1997;107(11 Pt 1):1469-1475.
26. Tanvetyanon T, Padhya T, McCaffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol. 2009;27(12):1983-1991.
27. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009;75(5):1493-1500.
28. Rwigema JC, Heron DE, Ferris RL, et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol. 2011;34(4):372-379.
29. Ozyigit G, Cengiz M, Yazici G, et al. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e263-e268.
30. Chen AM, Phillips TL, Lee NY Practical considerations in the re-irradiation of recurrent and second primary head-and-neck cancer: who, why, how, and how much? Int J Radiat Oncol Biol Phys. 2011;81(5):1211-1219.
31. Cacicedo J, Navarro A, Alongi F, et al. The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. Cancer Treat Rev. 2014;40(1):178-189.
32. Vargo JA, Heron DE, Ferris RL, et al. Examining tumor control and toxicity after stereotactic body radiotherapy in locally recurrent previously irradiated head and neck cancers: implications of treatment duration and tumor volume. Head Neck. 2014;36(9):1349-1355.
33. McDonald MW, Moore MG, Johnstone PA Risk of carotid blowout after reirradiation of the head and neck: a systematic review. Int J Radiat Oncol Biol Phys. 2012;82(3):1083-1089.
34. Yamazaki H, Ogita M, Kodani N, et al. Frequency, outcome and prognostic factors of carotid blowout syndrome after hypofractionated re-irradiation of head and neck cancer using CyberKnife: a multi-institutional study. Radiother Oncol. 2013;107(3):305-309.
35. Yazici G, Sanli TY, Cengiz M, et al. A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiaton for recurrent head and neck cancers. Radiat Oncol. 2013;8(1):242.